恶性疾病中T细胞受体的使用情况。 - Suppr

T cell receptor usage in malignant diseases.

作者信息

Halapi E, Jeddi-Tehrani M, Osterborg A, Mellstedt H

机构信息

deCODE Genetics Inc, Reykjavik, Island.

出版信息

Springer Semin Immunopathol. 1999;21(1):19-35. doi: 10.1007/BF00815176.

DOI:10.1007/BF00815176

PMID:10389230

Abstract

摘要

相似文献

T cell receptor usage in malignant diseases.

Springer Semin Immunopathol. 1999;21(1):19-35. doi: 10.1007/BF00815176.

Skewed T-cell receptor repertoire: more than a marker of malignancy, a tool to dissect the immunopathology of inflammatory diseases.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):153-61.

Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Curr Opin Immunol. 2018 Apr;51:103-110. doi: 10.1016/j.coi.2018.03.002. Epub 2018 Mar 16.

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.

T cell receptor usage in autoimmune disease.

Springer Semin Immunopathol. 1999;21(1):5-17. doi: 10.1007/BF00815175.

Cancer immunology. Cancer's bulwark against immune attack: MDS cells.

Science. 2008 Jan 11;319(5860):154-6. doi: 10.1126/science.319.5860.154.

A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.

J Immunother. 2016 Apr;39(3):105-16. doi: 10.1097/CJI.0000000000000116.

Armed T cells with CAR for cancer immunotherapy.

Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.

Semin Immunopathol. 2017 Apr;39(3):255-268. doi: 10.1007/s00281-016-0614-9. Epub 2017 Jan 10.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.

Hybridoma. 1999 Feb;18(1):57-61. doi: 10.1089/hyb.1999.18.57.

引用本文的文献

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.

Cancer Immunol Immunother. 2005 Jun;54(6):557-70. doi: 10.1007/s00262-004-0620-y. Epub 2004 Nov 27.

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9. doi: 10.1007/s00262-003-0420-9. Epub 2003 Sep 10.

本文引用的文献

In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.

Cancer Immunol Immunother. 1998 Oct;47(2):90-6. doi: 10.1007/s002620050508.

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.

Int J Cancer. 1998 Oct 5;78(2):202-8. doi: 10.1002/(sici)1097-0215(19981005)78:2<202::aid-ijc14>3.0.co;2-c.

Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.

Cancer Res. 1998 Jul 15;58(14):3078-86.

LAGE-1, a new gene with tumor specificity.

Int J Cancer. 1998 Jun 10;76(6):903-8. doi: 10.1002/(sici)1097-0215(19980610)76:6<903::aid-ijc22>3.0.co;2-1.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

J Immunother. 1998 May;21(3):198-204. doi: 10.1097/00002371-199805000-00005.

Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia.

Blood. 1998 Jun 1;91(11):4224-31.

Escape from host-antitumor immunity.

Crit Rev Oncog. 1997;8(2-3):111-41. doi: 10.1615/critrevoncog.v8.i2-3.10.

Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course.

Br J Haematol. 1998 Mar;100(4):655-63. doi: 10.1046/j.1365-2141.1998.00631.x.

Molecular characterisation of tumour infiltrating lymphocytes in oral squamous cell carcinoma.

Cancer Immunol Immunother. 1998 Mar;46(1):34-40. doi: 10.1007/s002620050457.

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

Blood. 1998 Apr 1;91(7):2459-66.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

T cell receptor usage in malignant diseases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

T cell receptor usage in malignant diseases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献